Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.

ABSTRACT:

Importance

Several anti-amyloid monoclonal antibodies have been developed for slowing the progression of Alzheimer disease (AD). Among the furthest developed are aducanumab, which received accelerated approval from the US Food and Drug Administration in 2021, and donanemab, which is currently undergoing phase 3 trials. The cost-effectiveness of these treatments has not been established.

Objectives

To estimate the cost-effectiveness of aducanumab and donanemab relative to standard care for early AD in the US.

Design, setting, and participants

A decision analytic model was used to estimate the lifetime health and economic outcomes of adults with early AD, from US healthcare sector and societal perspectives. Simulated patients had a mean (SD) age of 75.2 (5.5) years; 65%

SUBMITTER: Ross EL 

PROVIDER: S-EPMC8961406 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature